S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-2.14%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-2.14%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-2.14%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-2.14%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
Log in

NASDAQ:VYGR - Voyager Therapeutics Stock Price, Forecast & News

$8.76
-0.29 (-3.20 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$8.26
Now: $8.76
$9.11
50-Day Range
$6.80
MA: $10.73
$13.71
52-Week Range
$6.26
Now: $8.76
$28.79
Volume54,886 shs
Average Volume513,330 shs
Market Capitalization$325.43 million
P/E RatioN/A
Dividend YieldN/A
Beta2.19
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD101 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreements with AbbVie Inc.; Sanofi Genzyme; the University of Massachusetts; and MRI Interventions, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Voyager Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VYGR
CUSIPN/A
Phone857-259-5340

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$104.39 million
Book Value$2.68 per share

Profitability

Net Income$-43,600,000.00

Miscellaneous

Employees123
Market Cap$325.43 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.


Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions

How has Voyager Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Voyager Therapeutics' stock was trading at $9.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VYGR shares have decreased by 7.2% and is now trading at $8.75. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Voyager Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Voyager Therapeutics.

When is Voyager Therapeutics' next earnings date?

Voyager Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Voyager Therapeutics.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics Inc (NASDAQ:VYGR) announced its quarterly earnings data on Tuesday, March, 3rd. The company reported ($0.34) EPS for the quarter, beating the Zacks' consensus estimate of ($0.81) by $0.47. The business earned $32.67 million during the quarter, compared to analyst estimates of $9.25 million. Voyager Therapeutics had a negative net margin of 41.76% and a negative return on equity of 40.86%. View Voyager Therapeutics' earnings history.

What price target have analysts set for VYGR?

9 Wall Street analysts have issued twelve-month price targets for Voyager Therapeutics' shares. Their forecasts range from $14.00 to $27.00. On average, they anticipate Voyager Therapeutics' stock price to reach $19.63 in the next twelve months. This suggests a possible upside of 124.3% from the stock's current price. View analysts' price targets for Voyager Therapeutics.

What are Wall Street analysts saying about Voyager Therapeutics stock?

Here are some recent quotes from research analysts about Voyager Therapeutics stock:
  • 1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (3/18/2020)
  • 2. Nomura analysts commented, "Minor Tweaks Post-NBIX Collab., Revising Patient Numbers and Statistical Plan; No Data Guidance Yet. The first pivotal Parkinson’s disease trial, RESTORE-1, is undergoing minor modifications now that VYGR is partnered with NBIX. VYGR had previously guided to a 75-100 patient trial, but this is likely going to be clarified as the statistical analysis plan is finalized. No data guidance yet—but we expect an update when the target enrollment is finalized and when VYGR gets a sense of the pace of enrollment. Huntington’s Program IND by YE19 – Finalizing Clinical Team and Planning to Use Commercial-Grade Gene Therapy Material. Voyager recently attained full rights after the SNY collaboration restructuring (see our note here). VYGR plans to have an IND by YE19 and will use material that is “very, very similar” to commercial material to avoid any step back in the future." (8/13/2019)
  • 3. HC Wainwright analysts commented, "Our current target is based on a 12-year DCF analysis primarily focused on VY-AADC in PD. Our DCF analysis is based on: beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2030." (8/12/2019)

Has Voyager Therapeutics been receiving favorable news coverage?

Headlines about VYGR stock have been trending very positive this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Voyager Therapeutics earned a news impact score of 4.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutVoyager Therapeutics.

Who are some of Voyager Therapeutics' key competitors?

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Crispr Therapeutics (CRSP), Micron Technology (MU), TG Therapeutics (TGTX), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), ImmunoGen (IMGN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Clovis Oncology (CLVS) and Exelixis (EXEL).

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the following people:
  • Mr. Matthew P. Ottmer, Chief Operating Officer (Age 48)
  • Dr. Steven M. Paul, Exec. Science Advisor & Director (Age 68)
  • Mr. G. Andre Turenne, CEO, Pres & Director
  • Dr. Krystof Bankiewicz M.D., Ph.D., Founder
  • Dr. Guangping Gao Ph.D., Founder

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (3.58%), Renaissance Technologies LLC (3.36%), Casdin Capital LLC (2.95%), Bank of New York Mellon Corp (1.50%), Goldman Sachs Group Inc. (1.13%) and Nuveen Asset Management LLC (1.12%). Company insiders that own Voyager Therapeutics stock include Allison Dorval, Andre Turenne, Bernard Ravina, Glenn Pierce, James A Geraghty, Matthew P Ottmer and Neurocrine Biosciences Inc. View institutional ownership trends for Voyager Therapeutics.

Which institutional investors are selling Voyager Therapeutics stock?

VYGR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Nuveen Asset Management LLC, UBS Group AG, State Street Corp, Bank of America Corp DE, Citigroup Inc., Rafferty Asset Management LLC, and Raymond James Financial Services Advisors Inc.. Company insiders that have sold Voyager Therapeutics company stock in the last year include Allison Dorval, Andre Turenne, and Matthew P Ottmer. View insider buying and selling activity for Voyager Therapeutics.

Which institutional investors are buying Voyager Therapeutics stock?

VYGR stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Renaissance Technologies LLC, Bank of Montreal Can, Acadian Asset Management LLC, Russell Investments Group Ltd., Alberta Investment Management Corp, Man Group plc, and Bailard Inc.. Company insiders that have bought Voyager Therapeutics stock in the last two years include Glenn Pierce, James A Geraghty, and Neurocrine Biosciences Inc. View insider buying and selling activity for Voyager Therapeutics.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $8.75.

How big of a company is Voyager Therapeutics?

Voyager Therapeutics has a market capitalization of $325.06 million and generates $104.39 million in revenue each year. The company earns $-43,600,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Voyager Therapeutics employs 123 workers across the globe. View additional information about Voyager Therapeutics.

What is Voyager Therapeutics' official website?

The official website for Voyager Therapeutics is http://www.voyagertherapeutics.com/.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected]


MarketBeat Community Rating for Voyager Therapeutics (NASDAQ VYGR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  340 (Vote Outperform)
Underperform Votes:  287 (Vote Underperform)
Total Votes:  627
MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe VYGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VYGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel